Please login to the form below
CAR-T therapies
This page shows the latest CAR-T therapies news and features for those working in and with pharma, biotech and healthcare.
Soon-Shiong presents first data on cancer memory vaccine at SITC
According to Soon-Shiong, that approach should overcome the limitations of checkpoint inhibitor monotherapy, which only works in a proportion of patients, as well as cell-based CAR-T therapies that ... Patrick Soon-Shiong. In the prostate cancer trial,
Latest news
-
BCMA in the spotlight as ASH abstracts drop
BCMA in the spotlight as ASH abstracts drop. Updated results from promising CAR-T therapies are expected. ... candidates. The publication of the ASH abstracts yesterday revels no fewer than 51 presentations involving BCMA, including a slew of CAR-T
-
Celgene to launch five new products through to 2020
Celgene to launch five new products through to 2020. Two of which are CAR-T candidates. ... The late-stage pipeline is setting Celgene up for a busy American Society of Haematology (ASH) meeting in December, with new data expected on both CAR-T therapies
-
Gilead strikes deal with NHS England on CAR-T Yescarta
Dr Alasdair Rankin, Director of Research and Patient Experience at Bloodwise, said: “CAR-T therapies have shown huge promise in treating patients with lymphoma who have no other chance of cure. ... It is likely that we are only beginning to see the
-
Novartis cuts manufacturing jobs in Switzerland and UK
CAR-T drug Kymriah. ... The company is currently struggling to scale up its CAR-T production worldwide, and wants to divert more investment into the technology.
-
Kymriah rejected in DLBCL - but NICE wants to keep talking about cost effectiveness
NHS England’s commissioning expert told NICE that healthcare professionals would require “extensive training in managing and supporting patients”who had received CAR-T therapies, and that a new service specification ... NICE's Meindert Boysen.
More from news
Approximately 3 fully matching, plus 40 partially matching documents found.
Latest Intelligence
-
Cancer immunotherapy: What's on the horizon?
antigen receptor T-cell (CAR-T) therapies from Novartis and Gilead gained regulatory approval in 2017 for acute lymphoblastic leukaemia (ALL) and diffuse large B-cell lymphoma (DLBCL) after showing remarkable ... The challenges ahead are to improve the
-
The good, the bad and the ugly
The company hopes its $12bn acquisition of Kite Pharma (August 2017) will help it steal a march on the lucrative CAR-T market through its treatment for advanced lymphoma. ... It will also be interesting to see how gene therapies and cell-based therapies,
-
Cell and gene therapies: on course for commercial success?
The data for the research was derived from published data on CAR-T pipeline therapies, but was not related to any particular product. ... transplant. As a result, there may be no existing mechanism for these centres to obtain funding for any additional,
-
Deal Watch November 2016
were thought to be a result of the chemotherapy regimen used to prepare the patients before administering the CAR T cell therapy. ... their own CAR T cell therapies - so CAR T cell therapy seems to be still alive and doing well.
-
Deal Watch September 2016
The lead programme EM801 is a T cell bispecific antibody targeting B-cell maturation antigen (BCMA), which s considered to be complementary to Bluebird bio's CAR T cell therapies targeting ... 800. Arrowhead / Amgen. Licences. 2 agreements to develop and
More from intelligence
Approximately 0 fully matching, plus 11 partially matching documents found.
Latest appointments
-
Marinomed appoints CFO, Robin Brown is named chair of Medicines Discovery Catapult, Filippo Petti joins Ceylad and Vivienne Fox to chair RFI
Ceylad appoints new CFO. Clinical-stage biopharma focused on the development of CAR-T cell therapies has announced that Filippo Petti has been appointed as Chief Financial Officer. ... He said: “Celyad’s differentiated approach to the field of CAR-T
More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.
Latest from PMHub
-
Training the next generation of biotech leaders
In this year alone, the FDA has taken the groundbreaking step of approving two CAR-T therapies. ... From dream to reality. The approval of two CAR-T therapies this year illustrates how cell and gene therapies are turning from scientific dream to reality,
-
Addressing the biggest challenges for rare disease communities
It is common that primary care physicians either do not recognise specific symptoms or don’ t make the link between common symptoms and a rare disease. ... And just last year, we saw landmark breakthroughs in advanced genetic therapies, such as viral
-
Addressing the biggest challenges for rare disease communities
It is common that primary care physicians either do not recognise specific symptoms or don’ t make the link between common symptoms and a rare disease. ... And just last year, we saw landmark breakthroughs in advanced genetic therapies, such as viral
More from PMHub
Approximately 0 fully matching, plus 3 partially matching documents found.
Featured jobs
- Account Manager, Healthcare Public Affairs
-
£32, 000 – £40, 000 benefits
- Account Manager, Healthcare Communications
-
£32, 000 - £40, 000 bonus benefits
- Director, Market Access / HEOR - North-West
-
Negotiable
-
Senior Medical Writer
-
Great salary and benefits
-
Senior Account Manager
-
Negotiable
-
New Business Director - PR
-
Competitive Salary and benefits
- Senior Account Managers - Oxfordshire
-
Attractive salary and benefits package offered
- Scientific Director / Editorial Team Leader
-
Great salary and benefits
-
Associate Director
-
£75, 000-90, 000
- Leadership opportunity, Pricing & Market Access, UK, Substan...
-
Substantial six figure package
- Account Manager, Healthcare Communications
-
£32, 000 - £40, 000 bonus benefits
-
Account Director
-
£48, 000 - £60, 000
- Senior Account Director development role to Business Director, H...
-
Excellent package
- Senior Systematic Review Analyst - Oxford
-
Negotiable
-
Medical/ Scientific Director
-
Salary TBC
-
Associate Medical Director
-
Highly Competitive
-
Senior Medical Writer
-
Competitive Salary
-
Account Director
-
Excellent benefits
Subscribe to our email news alerts
- Confocal Microscope Market to Witness Notable Revenue Growth in North America Owing to Increasing Spending on R&D Initiatives in the Region
- Confocal Microscope Market to Witness Notable Revenue Growth in North America Owing to Increasing Spending on R&D Initiatives in the Region
- Carpal Tunnel Release Systems Market to reach a market valuation worth US$ 839.1 Mn by the end of 2028
- Digital Radiography Detectors Market to reach a valuation of US$ 2,713.7 Mn by 2026, exhibiting a promising 6.1% CAGR during 2018-2026.
- Analgesics Market is anticipated to reach a whopping US$ 79 Bn by 2028 end
- High Cost Factor and Health Risks Arising from Surgical Procedures Restraining Revenues in the Hearing Implant Market
PMHub
M3 (EU)
M3 was founded in 2000 with the goal of changing the world of medicine through making full use of the...
Latest intelligence
- Innovation in merger control and the impact on the pharmaceutical sector
- Is focusing on pipeline products enough to assess regulatory risks?...
- Nudge-nudge, think-think
- Chris Ross examines the personal complexities of human behaviour – and explains why fun, emotion and peer endorsement could be key to designing effective behavioural change programmes...
- Quality in Care Diabetes 2018: the best in innovative diabetes care
- Awards highlight new evidence-based approaches to improving care...
Quick links
Infographics
